Your browser doesn't support javascript.
loading
Safe and Effective Lip Enhancement with VYC-15L in Chinese Adults.
Li, Dong; Gao, Zhanwei; Sun, Jiaming; Li, Qin; Jiang, Ping; Zhang, Lijuan; Chawla, Smita.
Afiliação
  • Li D; Peking University Third Hospital, Beijing, People's Republic of China.
  • Gao Z; Japan Friendship Hospital, Beijing, People's Republic of China.
  • Sun J; Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Li Q; General Hospital of Guangzhou Military Command of PLA, Guangzhou, People's Republic of China.
  • Jiang P; Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
  • Zhang L; Allergan Aesthetics, an AbbVie Company, Beijing, People's Republic of China.
  • Chawla S; Clinical Development, Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA.
Clin Cosmet Investig Dermatol ; 15: 2427-2436, 2022.
Article em En | MEDLINE | ID: mdl-36387967
Background: Hyaluronic acid (HA) soft tissue fillers are used to restore volume loss to the lips and perioral area. Objective: Evaluate the safety and effectiveness of the HA filler Juvéderm® Volbella® (VYC-15L) for lip enhancement in Chinese adults. Methods & Materials: In this multicenter, evaluator-blind study, subjects seeking lip enhancement were randomized 3:1 to VYC-15L or no-treatment control group (with optional treatment delayed by 3 months). Effectiveness endpoints included 1-point improvement on the 5-point Lip Fullness Scale (LFS) assessed by evaluating investigators (EIs) and subjects, and overall volume of lips and change in lip surface area measured from 3-dimensional images. Safety assessments included procedural pain, injection site reactions (ISRs), and adverse events (AEs). Results: The modified intention-to-treat population included 163 subjects (median age, 34 years; 96.9% female). More VYC-15L-treated subjects had a 1-point reduction in EI-reported LFS score at month 3 versus untreated controls (84.7% vs 0%; p < 0.0001), and 65% of the treated subjects self-reported a 1-point LFS improvement at month 3. Procedural pain during injection was mild. The most common ISRs were swelling, tenderness to touch, and firmness. One treatment-related serious AE (injection site compression arterial ischemia) resolved in 16 days. Conclusion: VYC-15L treatment was superior to no treatment at 3 months and was well tolerated by subjects. Clinical Trial Registration Number: NCT03519204.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Cosmet Investig Dermatol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Cosmet Investig Dermatol Ano de publicação: 2022 Tipo de documento: Article